Biovie Inc (BIVI)

$1.99 +0.04 (1.79%)
Market Cap 16.48M
Revenue (ttm) 0.00
Net Income (ttm) -22.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,411,688
Avg Vol 5,643,742
Day's Range N/A - N/A
Shares Out 8.45M
Stochastic %K 35%
Beta 0.60
Analysts Strong Buy
Price Target $12.00

Company Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 775 888 3162
Address:
680 W. Nye Lane, Suite 204, Carson City, United States
TJ12000
TJ12000 Aug. 24 at 7:14 PM
$BIVI greaseball cong going to flip on incognito mode soon when this gyp scam takes a shit!
0 · Reply
DJS287
DJS287 Aug. 24 at 4:51 PM
$BIVI 👀
0 · Reply
TA_Kongen
TA_Kongen Aug. 24 at 4:41 PM
$BIVI Watching this here now. 2 break watch.
0 · Reply
sahcrete
sahcrete Aug. 24 at 4:41 PM
$BIVI Where are my bulls???
0 · Reply
TJ12000
TJ12000 Aug. 24 at 12:58 PM
$BIVI sink this gypsy company… highly concentrated snake oil. I ll stick with Tylenol when I catch Covid.
1 · Reply
sahcrete
sahcrete Aug. 24 at 12:33 PM
$BIVI so confused on why it’s dropping
0 · Reply
Itinerant
Itinerant Aug. 24 at 11:58 AM
$BIVI I am long with a small starter. However, this company has a large warrant/option over hang. This fact may constrain the ability of the stock to move up. I hope not. I appreciate the near term focus on Parkinson's, but I am more interested in AD over all, and this tech offers an additional gen 2 MOA attack on AD.
0 · Reply
emilyparkerr
emilyparkerr Aug. 24 at 10:21 AM
$BIVI update: SUNRISE-PD Phase 2 results published Aug 6 — bezisterim showed statistically significant motor + non-motor improvements in early Parkinson's. Inflammation biomarkers reduced. Phase 3 planned. Now watching ADDRESS-LC Long COVID data — expected 2nd/3rd week September. https://investors.bioviepharma.com/overview/default.aspx
0 · Reply
ewuzi01
ewuzi01 Aug. 24 at 1:26 AM
$BIVI
0 · Reply
Musklehed
Musklehed Aug. 23 at 9:01 PM
$BIVI •Approval Scenario Jump: If bezisterim clears Phase 3 trials and gains formal FDA approval for even one of its core indications, micro-cap biotechs traditionally experience immediate 500% to 1,000%+ rallies as they transition from speculative assets to commercial-stage entities with multi-billion dollar addressable markets.
1 · Reply
Latest News on BIVI
BioVie Registration statement: Registration filing

Aug 14, 2026, 8:00 AM EDT - 10 days ago

BioVie Registration statement: Registration filing

BioVie Annual report: Q4 2026

Aug 13, 2026, 7:00 AM EDT - 11 days ago

BioVie Annual report: Q4 2026

BioVie Transcript: Study result

Aug 12, 2026, 4:15 PM EDT - 11 days ago

BioVie Transcript: Study result

BioVie Slides: Study result

Aug 12, 2026, 4:15 PM EDT - 11 days ago

BioVie Slides: Study result

BioVie Press release: Study result

Aug 12, 2026, 4:15 PM EDT - 11 days ago

BioVie Press release: Study result

BioVie says Phase 2 SUNRISE-PD trial of bezisterim met primary endpoint

2026-08-06T13:26:51.000Z - 18 days ago

BioVie says Phase 2 SUNRISE-PD trial of bezisterim met primary endpoint

BioVie Registration statement: Registration filing

Aug 6, 2026, 8:00 AM EDT - 18 days ago

BioVie Registration statement: Registration filing

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Aug 6, 2026, 7:30 AM EDT - 18 days ago

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

BioVie Registration statement: Registration filing

Jul 31, 2026, 8:00 AM EDT - 24 days ago

BioVie Registration statement: Registration filing

BioVie files to sell Class A common stock, warrants, no amount given

2026-07-17T21:25:11.000Z - 5 weeks ago

BioVie files to sell Class A common stock, warrants, no amount given

BioVie Registration statement: Registration filing

Jul 17, 2026, 8:00 AM EDT - 5 weeks ago

BioVie Registration statement: Registration filing

BioVie files $300M mixed securities shelf

2026-06-18T21:25:09.000Z - 2 months ago

BioVie files $300M mixed securities shelf

BioVie Registration statement: Registration filing

Jun 18, 2026, 8:00 AM EDT - 2 months ago

BioVie Registration statement: Registration filing

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Jun 5, 2026, 3:31 PM EDT - 2 months ago

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?

BioVie Transcript: Investor update

Jun 2, 2026, 4:15 PM EDT - 2 months ago

BioVie Transcript: Investor update

BioVie Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 2 months ago

BioVie Slides: Corporate presentation

Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2

May 27, 2026, 8:00 AM EDT - 3 months ago

Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2

BioVie announces full enrollment of ADDRESS-LC trial of bezisterim

2026-05-26T12:32:11.000Z - 3 months ago

BioVie announces full enrollment of ADDRESS-LC trial of bezisterim

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

May 26, 2026, 8:00 AM EDT - 3 months ago

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease

2026-05-18T12:08:40.000Z - 3 months ago

BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

May 18, 2026, 8:00 AM EDT - 3 months ago

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

BioVie Quarterly report: Q3 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

BioVie Quarterly report: Q3 2026

BioVie Transcript: KOL event

May 7, 2026, 2:00 PM EDT - 3 months ago

BioVie Transcript: KOL event

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 11:30 AM EDT - 4 months ago

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Apr 14, 2026, 8:00 AM EDT - 4 months ago

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie Slides: Corporate presentation

Apr 1, 2026, 7:00 AM EDT - 5 months ago

BioVie Slides: Corporate presentation

BioVie Transcript: Status update

Mar 4, 2026, 4:15 PM EST - 6 months ago

BioVie Transcript: Status update

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Feb 12, 2026, 12:12 PM EST - 6 months ago

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

BioVie Quarterly report: Q2 2026

Feb 6, 2026, 7:00 AM EST - 7 months ago

BioVie Quarterly report: Q2 2026

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

2026-01-08T13:43:03.000Z - 8 months ago

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 24, 2025, 2:05 PM EST - 8 months ago

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

Nov 19, 2025, 8:00 AM EST - 9 months ago

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

BioVie Transcript: AGM 2025

Nov 10, 2025, 2:00 PM EST - 10 months ago

BioVie Transcript: AGM 2025

BioVie Quarterly report: Q1 2026

Nov 10, 2025, 7:00 AM EST - 10 months ago

BioVie Quarterly report: Q1 2026

BioVie Transcript: Investor Update

Oct 8, 2025, 4:15 PM EDT - 11 months ago

BioVie Transcript: Investor Update

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

Sep 26, 2025, 8:00 AM EDT - 11 months ago

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

BioVie Proxy statement: Proxy Filing

Sep 25, 2025, 8:00 AM EDT - 11 months ago

BioVie Proxy statement: Proxy Filing

BioVie price target adjusted to $12 from $6 at Brookline

2025-08-29T17:10:18.000Z - 1 year ago

BioVie price target adjusted to $12 from $6 at Brookline

BioVie Annual report: Q4 2025

Aug 15, 2025, 7:00 AM EDT - 1 year ago

BioVie Annual report: Q4 2025

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Aug 13, 2025, 4:05 PM EDT - 1 year ago

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Why Is BioVie Stock (BIVI) Down 50% Today?

2025-08-09T00:43:00.000Z - 1 year ago

Why Is BioVie Stock (BIVI) Down 50% Today?

BioVie 6M share Secondary priced at $2.00

2025-08-08T00:50:12.000Z - 1 year ago

BioVie 6M share Secondary priced at $2.00

BioVie Inc. Announces Pricing of $12 Million Public Offering

Aug 7, 2025, 8:43 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of $12 Million Public Offering

BioVie Registration statement: Registration Filing

Aug 4, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

BioVie presents data on Bezisterim at WCAG-2025

2025-07-24T12:20:32.000Z - 1 year ago

BioVie presents data on Bezisterim at WCAG-2025

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

Jul 24, 2025, 8:00 AM EDT - 1 year ago

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

BioVie appoints Amy Chappell, Kameel Farag to board of directors

2025-07-22T12:11:30.000Z - 1 year ago

BioVie appoints Amy Chappell, Kameel Farag to board of directors

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Jul 22, 2025, 8:00 AM EDT - 1 year ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

BioVie Registration statement: Registration Filing

Jul 22, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

BioVie Registration statement: Registration Filing

Jul 11, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

BioVie reports results from bezisterim Phase 3 NM101 study

2025-07-09T12:22:03.000Z - 1 year ago

BioVie reports results from bezisterim Phase 3 NM101 study

BioVie Inc. trading halted, news pending

2025-07-03T20:50:10.000Z - 1 year ago

BioVie Inc. trading halted, news pending

BioVie Registration statement: Registration Filing

Jul 3, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

2025-06-26T12:16:13.000Z - 1 year ago

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Jun 26, 2025, 8:00 AM EDT - 1 year ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

Jun 24, 2025, 4:05 PM EDT - 1 year ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

BioVie Transcript: AGM 2025

Jun 23, 2025, 5:00 PM EDT - 1 year ago

BioVie Transcript: AGM 2025

BioVie Proxy statement: Proxy Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

BioVie Transcript: Status Update

May 28, 2025, 12:00 PM EDT - 1 year ago

BioVie Transcript: Status Update

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

2025-05-15T12:11:23.000Z - 1 year ago

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

BioVie to host KOL event on Phase 2 study of bezisterim

2025-05-14T11:57:58.000Z - 1 year ago

BioVie to host KOL event on Phase 2 study of bezisterim

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

BioVie Quarterly report: Q3 2025

May 11, 2025, 6:00 PM EDT - 1 year ago

BioVie Quarterly report: Q3 2025

BioVie Proxy statement: Proxy Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

BioVie to present design of Phase 2 SUNRISE-PD trial

2025-05-07T12:24:31.000Z - 1 year ago

BioVie to present design of Phase 2 SUNRISE-PD trial

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

BioVie Quarterly report: Q2 2025

Feb 10, 2025, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q2 2025

BioVie Quarterly report: Q2 2025

Feb 10, 2025, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q2 2025

BioVie Registration statement: Registration Filing

Nov 27, 2024, 7:00 AM EST - 1 year ago

BioVie Registration statement: Registration Filing

BioVie Registration statement: Registration Filing

Nov 21, 2024, 7:00 AM EST - 1 year ago

BioVie Registration statement: Registration Filing

BioVie Quarterly report: Q1 2025

Nov 12, 2024, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q1 2025

BioVie Transcript: AGM 2024

Nov 7, 2024, 1:00 PM EST - 1 year ago

BioVie Transcript: AGM 2024

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 4:10 PM EDT - 1 year ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 24, 2024, 4:10 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 23, 2024, 3:24 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Proxy statement: Proxy Filing

Oct 22, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 15, 2024, 8:00 AM EDT - 2 years ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 11, 2024, 9:00 AM EDT - 2 years ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

BioVie Annual report: Q4 2024

Sep 29, 2024, 6:00 PM EDT - 2 years ago

BioVie Annual report: Q4 2024

BioVie Proxy statement: Proxy Filing

Sep 27, 2024, 8:00 AM EDT - 2 years ago

BioVie Proxy statement: Proxy Filing

BioVie Inc. Announces Closing of Public Offering

Sep 25, 2024, 4:05 PM EDT - 2 years ago

BioVie Inc. Announces Closing of Public Offering

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 10:26 PM EDT - 2 years ago

BioVie Inc. Announces Pricing of Public Offering

BioVie Inc. Announces Proposed Public Offering

Sep 23, 2024, 4:05 PM EDT - 2 years ago

BioVie Inc. Announces Proposed Public Offering

BioVie Proxy statement: Proxy Filing

Sep 17, 2024, 8:00 AM EDT - 2 years ago

BioVie Proxy statement: Proxy Filing

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 16, 2024, 8:00 AM EDT - 2 years ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 2 years ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 27, 2024, 8:45 AM EDT - 2 years ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 8, 2024, 6:00 AM EDT - 2 years ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

BioVie Inc. Announces Reverse Stock Split

Aug 6, 2024, 4:40 PM EDT - 2 years ago

BioVie Inc. Announces Reverse Stock Split

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 5, 2024, 9:00 AM EDT - 2 years ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 21, 2024, 9:00 AM EDT - 2 years ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Jun 20, 2024, 8:00 AM EDT - 2 years ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

TJ12000
TJ12000 Aug. 24 at 7:14 PM
$BIVI greaseball cong going to flip on incognito mode soon when this gyp scam takes a shit!
0 · Reply
DJS287
DJS287 Aug. 24 at 4:51 PM
$BIVI 👀
0 · Reply
TA_Kongen
TA_Kongen Aug. 24 at 4:41 PM
$BIVI Watching this here now. 2 break watch.
0 · Reply
sahcrete
sahcrete Aug. 24 at 4:41 PM
$BIVI Where are my bulls???
0 · Reply
TJ12000
TJ12000 Aug. 24 at 12:58 PM
$BIVI sink this gypsy company… highly concentrated snake oil. I ll stick with Tylenol when I catch Covid.
1 · Reply
sahcrete
sahcrete Aug. 24 at 12:33 PM
$BIVI so confused on why it’s dropping
0 · Reply
Itinerant
Itinerant Aug. 24 at 11:58 AM
$BIVI I am long with a small starter. However, this company has a large warrant/option over hang. This fact may constrain the ability of the stock to move up. I hope not. I appreciate the near term focus on Parkinson's, but I am more interested in AD over all, and this tech offers an additional gen 2 MOA attack on AD.
0 · Reply
emilyparkerr
emilyparkerr Aug. 24 at 10:21 AM
$BIVI update: SUNRISE-PD Phase 2 results published Aug 6 — bezisterim showed statistically significant motor + non-motor improvements in early Parkinson's. Inflammation biomarkers reduced. Phase 3 planned. Now watching ADDRESS-LC Long COVID data — expected 2nd/3rd week September. https://investors.bioviepharma.com/overview/default.aspx
0 · Reply
ewuzi01
ewuzi01 Aug. 24 at 1:26 AM
$BIVI
0 · Reply
Musklehed
Musklehed Aug. 23 at 9:01 PM
$BIVI •Approval Scenario Jump: If bezisterim clears Phase 3 trials and gains formal FDA approval for even one of its core indications, micro-cap biotechs traditionally experience immediate 500% to 1,000%+ rallies as they transition from speculative assets to commercial-stage entities with multi-billion dollar addressable markets.
1 · Reply
StackinGreen
StackinGreen Aug. 23 at 7:10 PM
$BIVI 🔥🔥🔥
0 · Reply
StackinGreen
StackinGreen Aug. 23 at 6:40 PM
$BIVI
0 · Reply
George786
George786 Aug. 23 at 5:57 PM
$BIVI
0 · Reply
Mr_Ro_Bato
Mr_Ro_Bato Aug. 22 at 5:11 PM
$BIVI fuck I shoulda loaded the boat https://www.accessnewswire.com/newsroom/en/publishing-and-media/new-to-the-street-broadcasts-today-across-bloomberg-television-u.s.-latin-amer-1210741
0 · Reply
SinCity45
SinCity45 Aug. 22 at 4:21 AM
$OLOX Ready to see this launch Monday. $BTC.X Looking strong. OLOX ran to $3 and then came back down, back up Monday, going to be a violent reversal back up. $SUGP $ADXN $BIVI
1 · Reply
Mr_Ro_Bato
Mr_Ro_Bato Aug. 22 at 3:12 AM
$BIVI that week chart looks 👍🏼
0 · Reply
Khan68
Khan68 Aug. 21 at 11:47 PM
$VIVS These prices at these levels won't be here for much longer. VivoSim already has paying Chinese customers. Two initial programs came from: A Shanghai-based oncology biotech A Chengdu-based pharmaceutical company And the orders aren't just for basic testing. They include: GI toxicology screening GI efficacy profiling $BIVI $SLS $HOWL $IVF
1 · Reply
TJ12000
TJ12000 Aug. 21 at 11:03 PM
$BIVI all day over greaseball kongs bIScAMiUm
0 · Reply
NewsAndFilings
NewsAndFilings Aug. 21 at 10:06 PM
MicroCaps $IGC, $BIVI, $QTEX, $ORBS, $RIME: Sub-$1 Stocks to Watch Now https://thestreetreports.com/microcaps-igc-bivi-qtex-orbs-rime-sub-1-stocks-to-watch-now/
0 · Reply
waveridin
waveridin Aug. 21 at 9:30 PM
$BIVI only $2!!! Anyone need a bivi?
0 · Reply
Musklehed
Musklehed Aug. 21 at 7:58 PM
$BIVI
0 · Reply
Mervolo
Mervolo Aug. 21 at 7:55 PM
$BIVI sorry was napping. Hopefully setting up for some ah shenanigans💁‍♀️💁‍♀️💁‍♀️💁‍♀️
0 · Reply